Design Therapeutics

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Initial Data from Single-Ascending Dose Phase 1 Trial of DT-216 for Friedreich Ataxia Expected to be Reported in December 2022

Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results

Company On-track to Report Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 in the Fourth Quarter of 2022 Company On-track to Report Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 in the Fourth Quarter of 2022

Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022

CARLSBAD, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported that João Siffert, M.D., president and chief executive officer, and Sean Jeffries, Ph.D., chief operating officer, will participate in a fireside chat during the 2022 Jefferies Cell and Genetic Medicine Summit on Thursday, September 29, 2022, at 10:00 a.m. ET in NYC.

Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 Expected in the Fourth Quarter of 2022

Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results

CARLSBAD, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that João Siffert, M.D., president and chief executive officer, and Sean Jeffries, Ph.D., chief operating officer, will participate in a fireside chat during the 2022 Wedbush PacGrow Virtual Healthcare Conference on Wednesday, August 10, 2022, at 10:20 a.m. ET.

Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

CARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that João Siffert, M.D., president and chief executive officer, will present at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 8:30 a.m. ET in New York City.

Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference

Clinical Execution of Lead GeneTAC™ Molecule, DT-216, with Initiation of Phase 1 Trial for the Treatment of Friedreich Ataxia

Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results

Topline Data from Phase 1 Trial Expected in the Second Half of 2022

Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC™ Molecule for the Treatment of Friedreich Ataxia

Phase 1 Trial of DT-216, a Novel FA GeneTAC™  Molecule, in Patients with Friedreich Ataxia On Track to Begin Soon

Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

Treatment with GeneTAC™ Small Molecules Reduced Nuclear Foci and Restored Normal Splicing In Vitro, Supporting Further Development Treatment with GeneTAC™ Small Molecules Reduced Nuclear Foci and Restored Normal Splicing In Vitro, Supporting Further Development

Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC™ Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022

Phase 1 Trial of DT-216 in Patients with Friedreich Ataxia to Be Initiated Soon

Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia

CARLSBAD, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that João Siffert, M.D., president and chief executive officer, and Sean Jeffries, Ph.D., chief operating officer, will participate in a fireside chat during the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 11:20 a.m. ET.

Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced that Jae Kim, M.D., FACC, has been appointed as chief medical officer. Dr. Kim will play a pivotal role in leading clinical strategy and development, including the company's first clinical trial planned to begin in the first half of 2022.

Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer

Goldman Sachs initiated coverage of Design Therapeutics Inc (NASDAQ: DSGN) with a Sell rating and a $10 price target.  The analyst Madhu Kumar has caution about the Company's lead indication of Friedreich ataxia.

Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating

Clinical Initiation of Lead GeneTAC TM Program for Friedreich Ataxia On-track for the First Half of 2022

Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results

Data to be Presented during the 2021 Virtual Myotonic Dystrophy Foundation Annual Conference Data to be Presented during the 2021 Virtual Myotonic Dystrophy Foundation Annual Conference

Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1

Preclinical Data Support Initiation of Clinical Development of Lead GeneTAC Program for Friedreich Ataxia in the First Half of 2022

Design Therapeutics Reports GeneTAC™ Portfolio Progress and Second Quarter 2021 Results

CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that João Siffert, M.D., president and chief executive officer, will participate in a fireside chat during the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 1:20 p.m. ET.

Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced the appointments of industry veterans, Heather Behanna, Ph.D., principal of SR One, and Deepa Prasad, managing director of WestRiver Group, to its board of directors effective June 15, 2021.

Design Therapeutics Expands Board of Directors with Key Appointments

Successful $276 Million IPO Completed to Advance GeneTAC TM Programs for Friedreich Ataxia and Myotonic Dystrophy Type-1 Toward Clinical Development

Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results

CARLSBAD, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN) (“Design”), a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions, today announced the closing of its previously announced initial public offering of 13,800,000 shares of its common stock, which includes 1,800,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $20.00 per share. Including the option exercise, the aggregate gross proceeds to Design from the offering were approximately $276.0 million, before deducting the underwriting discounts and commissions and offering expenses. The shares began trading on the Nasdaq Global Select Market on March 26, 2021, under the ticker symbol “DSGN.”

Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

The stock price of Design Therapeutics Inc (NASDAQ: DSGN) has increased by 107.45% in its market debut. These are the details.

DSGN Stock Price Increased 107.45% In Market Debut: Details

CARLSBAD, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc., a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions, today announced the pricing of its initial public offering of 12,000,000 shares of its common stock at a price to the public of $20.00 per share. The gross proceeds to Design from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $240.0 million. All of the shares are being offered by Design. In addition, Design has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of its common stock at the initial public offering price less the underwriting discounts and commissions.

Design Therapeutics Announces Pricing of Initial Public Offering

Design Therapeutics has filed proposed terms for a $228 million IPO. The firm is developing treatments for Friedreich ataxia and myotonic dystrophy.

Design Therapeutics Seeks $228 Million In U.S. IPO

Design Therapeutics Inc. has set terms for its initial public offering, in which the California-based biopharmaceutical company focused on gene targeted chimeras (GeneTAC) expects to raise up to $240 million, and be valued at up to $1.08 billion. The company is offering 12 million share in the IPO, which is expected to price between $18 and $20 a share.

News for Design Therapeutics Stock (DSGN)